Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 6/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.43 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713219 | 0.85 | PDE7A (0.65) | PDE7ASMN1; SMN2PDE7BALDH1A1SLC6A2 | |
| SCHEMBL30338244 | 0.85 | PDE7A (0.65) | PDE7ASMN1; SMN2PDE7BALDH1A1SLC6A2 | |
| SCHEMBL10923003 | 0.83 | PDE7A (0.65) | PDE7ASMN1; SMN2PDE7BALDH1A1SLC6A2 | |
| SCHEMBL9186731 | 0.83 | PDE7A (0.56) | PDE7ASMN1; SMN2PDE7BALDH1A1L3MBTL1 | |
| SCHEMBL8881808 | 0.83 | MAPT (0.58) | PDE7ASMN1; SMN2IDO1PDE7BALDH1A1 | |
| SCHEMBL7665295 | 0.83 | PDE7A (0.67) | PDE7ASMN1; SMN2IDO1PDE7BL3MBTL1 | |
| SCHEMBL11760310 | 0.83 | PDE7A (0.56) | PDE7ASMN1; SMN2PDE7BALDH1A1SLC6A2 | |
| SCHEMBL875772 | 0.81 | PDE7A (0.78) | PDE7ASMN1; SMN2PDE7BALDH1A1SLC6A2 | |
| SCHEMBL31272173 | 0.81 | PDE7A (0.78) | PDE7ASMN1; SMN2PDE7BALDH1A1SLC6A2 | |
| SCHEMBL6743647 | 0.80 | PDE7A (0.73) | PDE7ASMN1; SMN2IDO1PDE7BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102131791-B | Dibenzothiepiazane derivatives and their use | ASTRAZENECA SWEDEN AB | 2014-12-24 | — | — | CN | claimed |
| CN-102131791-B | Dibenzothiepiazane derivatives and their use | ASTRAZENECA SWEDEN AB | 2014-12-24 | — | — | CN | disclosed |
| US-8653257-B2 | Dibenzothiazepine derivatives and uses thereof—424 | ASTRAZENECA AB (SE) | 2014-02-18 | — | — | US | disclosed |
| US-8653257-B2 | Dibenzothiazepine derivatives and uses thereof—424 | ASTRAZENECA AB (SE) | 2014-02-18 | — | — | US | disclosed |
| EP-2307389-B1 | DIBENZOTHIAZEPINE DERIVATIVE AND USE THEREOF | ASTRAZENECA AB (SE) | 2013-01-23 | — | — | EP | disclosed |
| US-20120202991-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF - 424 | ASTRAZENECA AB (SE) | 2012-08-09 | — | — | US | disclosed |
| US-20120202991-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF - 424 | ASTRAZENECA AB (SE) | 2012-08-09 | — | — | US | disclosed |
| US-8158618-B2 | Dibenzothiazepine derivatives and uses thereof—424 | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-8158618-B2 | Dibenzothiazepine derivatives and uses thereof—424 | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| CN-102131791-A | Dibenzothiepiazane derivatives and their use | ASTRAZENECA AB | 2011-07-20 | — | — | CN | disclosed |
| US-20110160184-A1 | Dibenzothiazepine Derivatives and Use Thereof | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | disclosed |
| US-20110160184-A1 | Dibenzothiazepine Derivatives and Use Thereof | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | disclosed |
| US-20090318415-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF - 424 | ASTRAZENECA AB (SE) | 2009-12-24 | — | — | US | disclosed |
| US-20090318415-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF - 424 | ASTRAZENECA AB (SE) | 2009-12-24 | — | — | US | disclosed |
| WO-2009154563-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND USE THEREOF | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
| US-7592454-B2 | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| WO-2005105082-A1 | SUBSTITUTED HEXAHYDRO-PYRIDOINDOLE DERIVATIVES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050239768-A1 | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318415-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF - 424 | DRD4, DRD2, GABBR1 | PDE7A 1159/4885SMN1; SMN2 4076/4885IDO1 1105/4885 |
| US-20110160184-A1 | Dibenzothiazepine Derivatives and Use Thereof | DRD2, DRD4, GABBR1 | PDE7A 1140/4885SMN1; SMN2 4470/4885IDO1 876/4885 |
| US-20050239768-A1 | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists | HTR1A, HTR7, HTR1D | PDE7A 203/4885SMN1; SMN2 2094/4885IDO1 660/4885 |
| US-20120202991-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF - 424 | DRD4, DRD2, GABBR1 | PDE7A 1159/4885SMN1; SMN2 4076/4885IDO1 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.